Cargando…

Spotlight on the 9-valent HPV vaccine

Starting in 2006, vaccination against human papillomavirus (HPV) has been progressively implemented in most developed countries. Two vaccines have been successfully used, a bivalent vaccine targeting HPV-related cancers (bHPV) and a quadrivalent vaccine (qHPV) targeting both HPV-related cancers and...

Descripción completa

Detalles Bibliográficos
Autor principal:	Lopalco, Pier Luigi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5191848/ https://www.ncbi.nlm.nih.gov/pubmed/28053505 http://dx.doi.org/10.2147/DDDT.S91018

Ejemplares similares

Use of 9-Valent Human Papillomavirus (HPV) Vaccine: Updated HPV Vaccination Recommendations of the Advisory Committee on Immunization Practices
por: Petrosky, Emiko, et al.
Publicado: (2015)

HPV and Cytology Testing in Women Undergoing 9-Valent HPV Opportunistic Vaccination: A Single-Cohort Follow Up Study
por: De Vincenzo, Rosa, et al.
Publicado: (2021)

Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States
por: Gee, Julianne, et al.
Publicado: (2016)

Cutaneous HPV and alpha-mucosal 9-valent HPV sero-status associations
por: Rahman, Shams, et al.
Publicado: (2017)

Clinical guideline for 9-valent HPV vaccine: Korean Society of Gynecologic Oncology Guideline
por: Min, Kyung-Jin, et al.
Publicado: (2019)

The Impact of 9-Valent HPV Vaccination on Couple Infertility Prevention: A Comprehensive Review
por: Ciavattini, Andrea, et al.
Publicado: (2021)

The distribution and pathogenic risk of non‐9‐valent vaccine covered HPV subtypes in cervical lesions
por: Ma, Mingjun, et al.
Publicado: (2022)

Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom
por: Owusu-Edusei, Kwame, et al.
Publicado: (2022)

Assessing the epidemiological impact on cervical cancer of switching from 4-valent to 9-valent HPV vaccine within a gender-neutral vaccination programme in Switzerland
por: Kind, André B., et al.
Publicado: (2020)

Health impact and cost-effectiveness of implementing gender-neutral vaccination with the 9-valent HPV vaccine in Hong Kong
por: Cheung, Tak Hong, et al.
Publicado: (2023)

Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV
por: Di Mario, Simona, et al.
Publicado: (2015)

Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy
por: Mennini, Francesco Saverio, et al.
Publicado: (2017)

Costs and Cost-Effectiveness of 9-Valent Human Papillomavirus (HPV) Vaccination in Two East African Countries
por: Kiatpongsan, Sorapop, et al.
Publicado: (2014)

Prevalence, Genotype Distribution, and Predictors against HPV Infections Targeted By 2-, 4-, 9-Valent HPV Vaccines among Japanese Males
por: Matsuzawa, Yukimasa, et al.
Publicado: (2020)

Epidemiologic and economic burden of HPV diseases in Spain: implication of additional 5 types from the 9-valent vaccine
por: López, Noelia, et al.
Publicado: (2018)

Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
por: Mahumud, Rashidul Alam, et al.
Publicado: (2020)

Real-Life Safety Profile of the 9-Valent HPV Vaccine Based on Data from the Puglia Region of Southern Italy
por: Di Lorenzo, Antonio, et al.
Publicado: (2022)

Correction: Cost-effectiveness evaluations of the 9-Valent human papillomavirus (HPV) vaccine: Evidence from a systematic review
por: Mahumud, Rashidul Alam, et al.
Publicado: (2023)

Corrigendum to “Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV”
por: Di Mario, Simona, et al.
Publicado: (2017)

Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials
por: Petersen, Lone K., et al.
Publicado: (2017)

Safety profile of the 9-valent human papillomavirus vaccine: assessment in prior quadrivalent HPV vaccine recipients and in men 16 to 26 years of age
por: Moreira, E. D., et al.
Publicado: (2017)

Safety of human papillomavirus vaccines: a review
por: Stillo, Michela, et al.
Publicado: (2015)

Countering vaccine hesitancy through immunization information systems, a narrative review
por: Gianfredi, Vincenza, et al.
Publicado: (2019)

Estimation of the overall burden of cancers, precancerous lesions, and genital warts attributable to 9-valent HPV vaccine types in women and men in Europe
por: Hartwig, Susanne, et al.
Publicado: (2017)

Engineering for an HPV 9-valent vaccine candidate using genomic constitutive over-expression and low lipopolysaccharide levels in Escherichia coli cells
por: Wang, Kaihang, et al.
Publicado: (2021)

2463. Post-licensure Surveillance of 9-Valent Human Papillomavirus Vaccine (9vHPV) in the Vaccine Adverse Event Reporting System (VAERS), United States, 2014–2017
por: Arana, Jorge, et al.
Publicado: (2018)

Safety of Human Papillomavirus 9-Valent Vaccine: A Meta-Analysis of Randomized Trials
por: Costa, Ana Paula Ferreira, et al.
Publicado: (2017)

Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence
por: SIGNORELLI, C., et al.
Publicado: (2017)

Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria
por: Boiron, L., et al.
Publicado: (2016)

Public health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals through age 45 years in the United States
por: Daniels, Vincent, et al.
Publicado: (2021)

Prevalence of high-risk HPV genotypes, categorised by their quadrivalent and nine-valent HPV vaccination coverage, and the genotype association with high-grade lesions
por: Paz-Zulueta, María, et al.
Publicado: (2018)

Seroprevalence and Associated Factors of 9-Valent Human Papillomavirus (HPV) Types among Men in the Multinational HIM Study
por: Rahman, Shams, et al.
Publicado: (2016)

A Broad Safety Assessment of the 9-Valent Human Papillomavirus Vaccine
por: Yih, W Katherine, et al.
Publicado: (2021)

Systemic lupus erythematosus following human papillomavirus 9-valent vaccination
por: Wan, Yuehua, et al.
Publicado: (2022)

Extended surveillance to assess safety of 9-valent human papillomavirus vaccine
por: Sundaram, Maria E., et al.
Publicado: (2022)

Spotlight on dream recall: the ages of dreams
por: Mangiaruga, Anastasia, et al.
Publicado: (2018)

Safety of COVID-19 Vaccines: Spotlight on Neurological Complications
por: Tondo, Giacomo, et al.
Publicado: (2022)

Human papillomavirus (HPV) in young women in Britain: Population-based evidence of the effectiveness of the bivalent immunisation programme and burden of quadrivalent and 9-valent vaccine types
por: Tanton, Clare, et al.
Publicado: (2017)

Viewpoint: vaccine inequity in the spotlight
por: Bittaye, Mustapha, et al.
Publicado: (2022)

Highly pathogenic coronaviruses: thrusting vaccine development in the spotlight
por: He, Chunting, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_jjhj39vap1c6qgbpv43sgboip5